Jones Hill Capital LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0002102314

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 Q2 2026 Q1 2026

Q3 2026 · 33 positions · Total reported value $589.17M · Top-10 concentration 68.1% · Updated 2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

Turnover: 81.2% · 19 new · 5 cut · 15 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -10.3% · vs SPY -12.4% · Prev Value $470.36M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -7.4% · vs SPY -9.6% · Latest Value $589.17M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Jones Hill Capital LP disclosed 33 equity positions with a combined reported value of $589.17M. The filing implies a focused portfolio: its ten largest positions account for 68.1% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were BMRN ($70.31M), BCRX ($59.00M), TVTX ($56.50M). By sector, the heaviest allocations are Health Care 100.0%. Versus the prior quarter, allocation shifted toward Health Care (+2.6pp) and away from Other (-2.6pp).

Versus the prior quarter, Jones Hill Capital LP opened 19 new positions, trimmed 5 and fully exited 15, a turnover rate of 81.2% of positions. The portfolio's overlap with the prior quarter was 29% of names.

The largest new positions opened in Q3 2026 were BCRX ($59.00M), TVTX ($56.50M), INDV ($54.73M).

Of the 15 positions fully exited versus the prior quarter, the largest were GILD ($43.34M), ARQT ($28.57M), MDGL ($28.21M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • BCRX BIOCRYST PHARMACEUTICALS INC · $59.00M
  • TVTX TRAVERE THERAPEUTICS INC · $56.50M
  • INDV INDIVIOR PHARMACEUTICALS INC · $54.73M
  • CELC CELCUITY INC · $30.45M
  • IONS IONIS PHARMACEUTICALS INC · $26.78M
  • SUPN SUPERNUS PHARMACEUTICALS · $25.90M
  • NUVB NUVATION BIO INC · $25.13M
  • VERA VERA THERAPEUTICS INC · $21.06M

Fully Exited (vs previous quarter)

  • GILD GILEAD SCIENCES INC · prev qtr: $43.34M
  • ARQT ARCUTIS BIOTHERAPEUTICS INC · prev qtr: $28.57M
  • MDGL MADRIGAL PHARMACEUTICALS INC · prev qtr: $28.21M
  • XENE XENON PHARMACEUTICALS INC · prev qtr: $22.21M
  • ANIP ANI PHARMACEUTICALS INC · prev qtr: $19.35M
  • AMLX AMYLYX PHARMACEUTICALS INC · prev qtr: $16.06M
  • NUVL NUVALENT INC · prev qtr: $12.16M
  • IMUX IMMUNIC INC · prev qtr: $8.30M

Insider Transactions (Form 4)

Latest Jones Hill Capital LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Jones Hill Capital LP, based in New York, NY, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 29 positions worth $470.36M in total. HoldingsHub carries 2 quarters of its filings (Q1 2026–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-135105 (status: Approved), registered 2026-01-06
  • Regulatory AUM (Form ADV): $642.42M as of 2026-05-06
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 1 private funds, of which 1 hedge funds
  • Website: joneshillcapital.com

Portfolio Structure

  • 29 positions · $470.36M reported value (Q2 2026)
  • Top 10 holdings = 68.8% of reported value
  • Largest position: BMRN (BIOMARIN PHARMACEUTICAL INC) at 17.4%
  • Average position size: $16.22M

Sector Tilt

  • Health Care 97.4%
  • (classified holdings cover 97% of value)

Quarterly Activity

  • Q2 2026: 15 new, 5 added, 9 reduced, 12 exited

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: Aggressive rotation into new biotech/healthcare positions, reducing exposure to BioMarin while adding 9 new healthcare stocks, suggesting a bullish but selective view on biotech innovation. 2. Key moves: - Reduced: BMRN (BioMarin) by 18.1% shares (QoQ). - Added: PHVS (Pharvaris) by 45.7% shares (QoQ). - New positions: BCRX, TVTX, INDV, CELC, IONS, SUPN, NUVB, VERA (all healthcare, no prior holdings). 3. Portfolio structure: Highly active, concentrated in healthcare (100% of top 10), high-risk (small/mid-cap biotech focus), benchmark-agnostic (no ETFs). 4. Per-holding one-liner: - BMRN: BioMarin (unverified, likely biopharma). - BCRX: BioCryst (unverified, likely rare disease drugs). - TVTX: Trever (unverified, likely kidney disease). - INDV: Indivior (unverified, likely addiction treatment). - PHVS: Pharvaris (unverified, likely rare disease). - CELC: Celcuity (unverified, likely oncology). - IONS: Ionis (unverified, likely RNA therapeutics). - SUPN: Supernus (unverified, likely CNS disorders). - NUVB: Nuvation (unverified, likely biotech). - VERA: Vera (unverified, likely pulmonology). 5. Style summary: Rotating out of established biotech (BioMarin) into high-risk, high-reward new healthcare names.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-14 21:57

Sector Allocation

Health Care 100.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 1.17M $70.31M 11.93%
11.93%
Reduce
2 7.08M $59.00M 10.02%
10.02%
New
3 959.63K $56.50M 9.59%
9.59%
New
4 1.53M $54.73M 9.29%
9.29%
New
5 987.64K $31.33M 5.32%
5.32%
Add
6 382.90K $30.45M 5.17%
5.17%
New
7 599.83K $26.78M 4.55%
4.55%
New
8 601.68K $25.90M 4.39%
4.39%
New
9 4.49M $25.13M 4.26%
4.26%
New
10 652.22K $21.06M 3.58%
3.58%
New
11 1.45M $20.72M 3.52%
3.52%
Add
12 1.06M $19.81M 3.36%
3.36%
Add
13 5.24M $19.75M 3.35%
3.35%
Add
14 142.56K $14.12M 2.40%
2.40%
New
15 2.50M $13.17M 2.24%
2.24%
Add
16 106.53K $12.16M 2.06%
2.06%
Reduce
17 83.43K $11.83M 2.01%
2.01%
New
18 384.28K $11.64M 1.98%
1.98%
Reduce
19 610.12K $8.94M 1.52%
1.52%
New
20 892.53K $8.45M 1.44%
1.44%
Add
21 80.02K $7.05M 1.20%
1.20%
Add
22 217.70K $6.06M 1.03%
1.03%
New
23 886.43K $6.05M 1.03%
1.03%
Add
24 563.74K $5.49M 0.93%
0.93%
Reduce
25 502.59K $4.97M 0.84%
0.84%
New
26 300.90K $4.85M 0.82%
0.82%
New
27 126.74K $3.61M 0.61%
0.61%
New
28 182.29K $3.12M 0.53%
0.53%
New
29 276.83K $2.02M 0.34%
0.34%
Add
30 593.74K $2.01M 0.34%
0.34%
New
31 206.40K $1.78M 0.30%
0.30%
Reduce
32 122.17K $230.90K 0.04%
0.04%
New
33 26.70K $154.86K 0.03%
0.03%
New

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-12. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-12 Trading days31 Holdings4 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-12, and will update as prices arrive.

Portfolio return+4.82%Buy & hold
QQQ synthetic benchmark-11.15%Liquidity weighted
Excess return+15.97%vs benchmark
Barra annualised vol54.0%Model estimate
Realised vol50.4%Annualised in window
Weighted beta1.11Raw exposure
Factor / specific risk36% / 64%Share of variance
Top-10 concentration100.0%Of reported value
Portfolio value (start = 100)78.385.492.599.7106.810-0110-2211-12Jones Hill Capital LPQQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)+4.82%Disclosed long book
QQQ synthetic benchmark-11.15%Liquidity-weighted constituents
Model universe, equal weight+2.04%Opportunity-cost reference
Excess return+15.97%Portfolio − benchmark
Arithmetic return sum+6.22%Difference vs compounded is the cross term
Weighted raw beta1.11Weighted holding betas
Realised volatility (annualised)50.40%Daily returns in window
Barra model volatility (annualised)53.99%Factor + specific
Factor share of variance35.8%Barra factors
Specific share of variance64.2%Stock residuals
Reported value$23.3M13F long US equity

2. Return attribution

The +6.22% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 +1.30% 21.0%
Momentum & Growth 3 -0.75% -12.0%
Volatility & Tail Risk 7 +0.57% 9.2%
Industry 12 +9.47% 152.2%
Specific 1 -4.38% -70.4%
Return attribution (style + industry, %)-14.6-7.3+0.0+7.3+14.6Growth-0.51Amihud Illiquidity+0.61Short-term Reversal+0.77Momentum-1.01Beta+1.26Max Drawdown+1.62Mid Cap-1.81Leverage (Downside Vol)+1.84Size+2.35Residual Volatility+5.19Skewness-7.08Health Care+9.47Kurtosis+11.30Historical Volatility-13.56
Factor Type Exposure Factor return Contribution Share of |return|
Kurtosis Style +1.83 +6.17% +11.30% 181.8%
Health Care Industry +1.00 +9.47% +9.47% 152.2%
Residual Volatility Style +2.42 +2.15% +5.19% 83.5%
Size Style -1.22 -1.93% +2.35% 37.7%
Leverage (Downside Vol) Style -0.60 -3.05% +1.84% 29.6%
Max Drawdown Style -1.60 -1.01% +1.62% 26.1%
Beta Style +0.26 +4.92% +1.26% 20.3%
Short-term Reversal Style +0.69 +1.12% +0.77% 12.4%
Amihud Illiquidity Style +2.04 +0.30% +0.61% 9.8%
Non-linear Size Style +1.65 +0.07% +0.11% 1.8%
Turnover Style -0.03 -4.35% +0.11% 1.8%
Liquidity Style +0.36 -0.20% -0.07% -1.2%
Growth Style -0.34 +1.50% -0.51% -8.1%
Momentum Style +0.30 -3.32% -1.01% -16.3%
Mid Cap Style +0.94 -1.92% -1.81% -29.1%
Specific Specific — — -4.38% -70.4%
Skewness Style +1.48 -4.77% -7.08% -113.9%
Historical Volatility Style +1.38 -9.82% -13.56% -218.1%

3. Risk attribution

Annualised volatility is 53.99%; factor risk explains 35.8% of variance and specific risk 64.2%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-69.4-34.7+0.0+34.7+69.4Short-term Reversal-0.79Leverage (Downside Vol)-0.38Momentum+0.42Growth+0.52Size+1.03Mid Cap+1.08Non-linear Size+1.33Amihud Illiquidity+1.60Residual Volatility+3.01Skewness+3.39Max Drawdown+6.53Historical Volatility+7.58Health Care+9.72Specific+64.22
Factor Type Exposure Share of variance Vol contribution Share of vol
Specific Specific — 64.2% +34.67% 34.7%
Health Care Industry +1.00 9.7% +5.25% 5.2%
Historical Volatility Style +1.38 7.6% +4.09% 4.1%
Max Drawdown Style -1.60 6.5% +3.53% 3.5%
Skewness Style +1.48 3.4% +1.83% 1.8%
Residual Volatility Style +2.42 3.0% +1.63% 1.6%
Amihud Illiquidity Style +2.04 1.6% +0.86% 0.9%
Non-linear Size Style +1.65 1.3% +0.72% 0.7%
Mid Cap Style +0.94 1.1% +0.58% 0.6%
Size Style -1.22 1.0% +0.55% 0.6%
Growth Style -0.34 0.5% +0.28% 0.3%
Momentum Style +0.30 0.4% +0.22% 0.2%
Beta Style +0.26 0.4% +0.19% 0.2%
Kurtosis Style +1.83 0.2% +0.11% 0.1%
Leverage (Downside Vol) Style -0.60 -0.4% -0.20% -0.2%
Short-term Reversal Style +0.69 -0.8% -0.43% -0.4%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-2.0-0.80.41.62.8Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size -1.22 +2.10 -3.32
Non-linear Size +1.65 +1.68 -0.02
Mid Cap +0.94 +0.13 +0.82
Beta +0.26 +1.29 -1.04
Momentum +0.30 +0.72 -0.41
Short-term Reversal +0.69 -0.64 +1.33
Residual Volatility +2.42 -0.40 +2.82
Historical Volatility +1.38 +0.86 +0.52
Liquidity +0.36 +0.11 +0.24
Amihud Illiquidity +2.04 +1.16 +0.88
Turnover -0.03 +0.21 -0.23
Growth -0.34 +0.58 -0.92
Leverage (Downside Vol) -0.60 +0.14 -0.75
Skewness +1.48 +0.24 +1.25
Kurtosis +1.83 +0.21 +1.62
Max Drawdown -1.60 -0.08 -1.52

5. Industry allocation & Brinson

Industry allocation (weight, %)-10.020.050.080.0110.0Information TechnologyCommunication ServicesUtilitiesConsumer StaplesConsumer DiscretionaryIndustrialsHealth CarePortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Information Technology 0.0% 73.6% +0.00% -16.67% +4.61% +12.27% -12.27% +12.27%
Health Care 100.0% 1.7% +3.67% +9.50% +19.56% -0.10% -5.72% +3.51%
Communication Services 0.0% 2.6% +0.00% -12.15% +0.05% +0.32% -0.32% +0.32%
Utilities 0.0% 0.8% +0.00% +10.14% -0.16% -0.08% +0.08% -0.08%
Consumer Staples 0.0% 0.8% +0.00% +15.33% -0.22% -0.13% +0.13% -0.13%
Consumer Discretionary 0.0% 8.8% +0.00% +5.93% -1.44% -0.52% +0.52% -0.52%
Industrials 0.0% 11.1% +0.00% +7.87% -2.03% -0.87% +0.87% -0.87%
Total +20.28% +10.85% -16.67% +14.46%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
INSM INSMED INC Health Care 52.11% +5.79% +3.02% Reduce
NGNE NEUROGENE INC Health Care 25.95% -9.78% -2.54% New
SGMT SAGIMET BIOSCIENCES INC Health Care 21.28% +15.49% +3.29% New
ALVO ALVOTECH Health Care 0.66% -15.17% -0.10% New
Contribution rank Symbol Sector Weight Return Contribution
1 SGMT Health Care 21.28% +15.49% +3.29%
2 INSM Health Care 52.11% +5.79% +3.02%
3 ALVO Health Care 0.66% -15.17% -0.10%
4 NGNE Health Care 25.95% -9.78% -2.54%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-12 (31 trading days), the reported portfolio returned +4.82%, versus -11.15% for the QQQ synthetic benchmark — an excess of +15.97%.
  2. Return attribution: the largest positive style/industry contributions came from Kurtosis +11.30%, Health Care +9.47%, Residual Volatility +5.19%; the largest drags came from Historical Volatility -13.56%, Skewness -7.08%, Mid Cap -1.81%. Specific (stock-level) return contributed -4.38%.
  3. Risk attribution: Barra model volatility is 53.99% annualised; factor risk explains 36% of variance and specific risk 64%. The largest factor risk sources are Health Care 9.7%, Historical Volatility 7.6%, Max Drawdown 6.5%.
  4. Style tilt: size -1.22, momentum +0.30, volatility +1.38, liquidity +0.36; the weighted raw beta is 1.11. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Health Care (+98.3 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +20.28%, selection +10.85% and interaction -16.67%.
  6. Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did Jones Hill Capital LP buy in 2026-Q3?

In its 2026-Q3 13F filing, Jones Hill Capital LP reported 33 equity positions worth $589.17M in aggregate; its largest disclosed positions were BMRN ($70.31M), BCRX ($59.00M), TVTX ($56.50M).

How large is Jones Hill Capital LP's portfolio?

Jones Hill Capital LP reported $589.17M of long equity holdings across 33 positions as of 2026-Q3. Top-10 holdings account for 68.1% of reported value.

What is Jones Hill Capital LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/jones-hill-capital/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →